Immunovia AB (publ) (LON:0G8X)

Market Cap	9.98M +13.0%
Revenue (ttm)	62.06K +24.4%
Net Income	-9.91M
EPS	-4.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,000
Average Volume	64,779
Open	0.1978
Previous Close	0.2090
Day's Range	0.1978 - 0.2000
52-Week Range	0.1978 - 0.9250
Beta	2.76
RSI	32.81
Earnings Date	Feb 24, 2026

About Immunovia AB

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2007
• Employees: 12
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0G8X

Financial Performance

In 2024, Immunovia AB's revenue was 931,000, a decrease of -40.89% compared to the previous year's 1.58 million. Losses were -76.54 million, -75.26% less than in 2023.

Financial numbers in SEK